I
Isaac Brownell
Researcher at National Institutes of Health
Publications - 88
Citations - 3250
Isaac Brownell is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Merkel cell carcinoma & Skin cancer. The author has an hindex of 22, co-authored 68 publications receiving 2514 citations. Previous affiliations of Isaac Brownell include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman,Jeffery S. Russell,Omid Hamid,Shailender Bhatia,Patrick Terheyden,Sandra P. D'Angelo,Kent C. Shih,Céleste Lebbé,Gerald P. Linette,Michele Milella,Isaac Brownell,Karl D. Lewis,Jochen H. Lorch,Kevin M. Chin,Lisa Mahnke,Anja von Heydebreck,Jean Marie Cuillerot,Paul Nghiem +17 more
TL;DR: Treatment with avelumab was associated with durable responses, most of which are still ongoing, and was well tolerated; hence, a Velumab represents a new therapeutic option for advanced Merkel cell carcinoma.
Journal ArticleDOI
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
TL;DR: A patient with metastatic melanoma who received palliative radiation to his primary tumor with subsequent clearance of all his nonirradiated in-transit metastases is reported, demonstrating an association between the abscopal effect and a systemic antitumor immune response.
Journal ArticleDOI
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Howard L. Kaufman,Jeffery S. Russell,Omid Hamid,Shailender Bhatia,Patrick Terheyden,Sandra P. D'Angelo,Kent C. Shih,Céleste Lebbé,Michele Milella,Isaac Brownell,Karl D. Lewis,Jochen H. Lorch,Anja von Heydebreck,Meliessa Hennessy,Paul Nghiem +14 more
TL;DR: With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed following prior chemotherapy for metastatic disease.
Journal ArticleDOI
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
Paul W. Harms,Kelly L. Harms,Patrick S. Moore,James A. DeCaprio,Paul Nghiem,Michael K K Wong,Isaac Brownell +6 more
TL;DR: The availability of immune checkpoint inhibition has improved the outcomes of a subset of patients with MCC, although many unmet needs continue to exist, according to this Consensus Statement.
Journal ArticleDOI
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo,Sandra P. D'Angelo,Shailender Bhatia,Andrew S. Brohl,Omid Hamid,Janice M. Mehnert,Patrick Terheyden,Kent C. Shih,Isaac Brownell,Céleste Lebbé,Karl D. Lewis,Gerald P. Linette,Michele Milella,Sara Georges,Parantu K. Shah,Barbara Ellers-Lenz,Marcis Bajars,Gülseren Güzel,Paul Nghiem +18 more
TL;DR: High tumor mutational burden and high major histocompatibility complex class I expression were associated with trends for improved ORR and OS in patients with mMCC, reinforcing avelumab as a standard-of-care treatment option for this disease.